Diagnostic options · UAE

Genetic tests in Dubai & UAE

Compare available Genetic tests, their listed prices and the information provided for each option. Test selection and preparation should be discussed with your clinician.

Tests in this category

805

Listed price range

600.00–30,000.00 AED

Clinical preparation

Confirm test-specific instructions with your clinician or laboratory.

Compare available tests

Genetic test prices

Showing 46–60 of 805 matching tests.

Genetic diagnostic tests, details, and listed prices
Test and description	Specimen	Typical duration	Price	Options
TEST-6049 ALDH6A1 Gene Methylmalonate Semialdehyde Dehydrogenase Deficiency Genetic Test This genetic test identifies pathogenic variants in the ALDH6A1 gene associated with methylmalonate semialdehyde dehydrogenase deficiency.	Whole Blood	3–4 weeks with interim reports	2,800.00 AED	View
View test specifications and preparation Hide test specifications and preparation What it measures ["Pathogenic variants in the ALDH6A1 gene", "Enzyme deficiency related to ALDH6A1"] Parameters [] Preparation ["No fasting required", "Provide detailed clinical history", "Provide a three-generation pedigree chart"] Indications ["Suspected methylmalonate semialdehyde dehydrogenase deficiency", "Family history of the disorder", "Ambiguous biochemical results", "Carrier screening"] Measurement technique Confirm with laboratory Codes LOINC: 94046-3 ICD-10: E70.8 Clinical summary This genetic test identifies pathogenic variants in the ALDH6A1 gene associated with methylmalonate semialdehyde dehydrogenase deficiency.
TEST-6365 ALG12 Gene Glycosylation Disorder Type 1G Genetic Test This genetic test screens the entire ALG12 gene for pathogenic variants associated with Congenital Disorder of Glycosylation Type 1G (ALG12-CDG). It uses Next-Generation Sequencing...	Whole Blood (EDTA) – Peripheral Venous Blood	3–4 weeks	2,800.00 AED	View
View test specifications and preparation Hide test specifications and preparation What it measures ["Pathogenic variants in the ALG12 gene", "Single nucleotide variants (SNVs)", "Small insertions/deletions (indels)", "Copy number variants (CNVs)"] Parameters [] Preparation ["No specific fasting required", "Do not discontinue prescribed therapy"] Indications ["Suspected Congenital Disorder of Glycosylation Type 1G (ALG12-CDG)", "Individuals with clinical features suggestive of ALG12-CDG", "Family history of ALG12-CDG"] Measurement technique Confirm with laboratory Codes LOINC: 92789-1 ICD-10: E77.8 Clinical summary This genetic test screens the entire ALG12 gene for pathogenic variants associated with Congenital Disorder of Glycosylation Type 1G (ALG12-CDG). It uses Next-Generation Sequencing (NGS) with confirmatory Sanger sequencing.
TEST-4462 ALG6 Gene Glycosylation Disorder Type 1C Genetic Test This genetic test evaluates the ALG6 gene for mutations associated with Congenital Disorder of Glycosylation Type 1c.	Peripheral whole blood (EDTA) or FTA card	3–4 Weeks	2,800.00 AED	View
View test specifications and preparation Hide test specifications and preparation What it measures ["Mutations in the ALG6 gene", "Single-nucleotide variants", "Insertions", "Deletions", "Splice-site alterations"] Parameters [] Preparation ["No specific fasting required", "Inform lab of any current medications"] Indications ["Suspected Congenital Disorder of Glycosylation Type 1c", "Family history of CDG-1c", "Neurological symptoms consistent with CDG-1c"] Measurement technique Confirm with laboratory Codes LOINC: 82939-0 ICD-10: E77.8 Clinical summary This genetic test evaluates the ALG6 gene for mutations associated with Congenital Disorder of Glycosylation Type 1c.
TEST-6301 ALG9 Gene Genetic Test for Congenital Disorder of Glycosylation Type 1L (CDG-IL) This genetic test identifies mutations in the ALG9 gene associated with Congenital Disorder of Glycosylation Type 1L (CDG-IL).	Whole blood (EDTA), extracted DNA, or FTA card	15–20 working days	2,800.00 AED	View
View test specifications and preparation Hide test specifications and preparation What it measures ["ALG9 gene sequence", "Copy number variations in ALG9 gene"] Parameters [] Preparation ["Genetic counselling with pedigree chart mandatory prior to testing", "No fasting required for blood draw"] Indications ["Suspected Congenital Disorder of Glycosylation Type 1L (CDG-IL)", "Family history of CDG-IL"] Measurement technique Confirm with laboratory Codes LOINC: 81265-0 ICD-10: E77.8 Clinical summary This genetic test identifies mutations in the ALG9 gene associated with Congenital Disorder of Glycosylation Type 1L (CDG-IL).
TEST-4974 ALOXE3 Gene Test This diagnostic test evaluates the ALOXE3 gene for mutations associated with nonbullous congenital ichthyosiform erythroderma.	Peripheral Whole Blood	3–4 Weeks	2,800.00 AED	View
View test specifications and preparation Hide test specifications and preparation What it measures ["Point mutations in ALOXE3 gene", "Small indels in ALOXE3 gene", "Copy number variants in ALOXE3 gene"] Parameters [] Preparation [] Indications ["Diagnosis of nonbullous congenital ichthyosiform erythroderma", "Genetic counseling for families with a history of the condition"] Measurement technique Confirm with laboratory Codes LOINC: 81247-9 ICD-10: Q80.2 Clinical summary This diagnostic test evaluates the ALOXE3 gene for mutations associated with nonbullous congenital ichthyosiform erythroderma.
TEST-163 Alpha-1-Antitrypsin (AAT) Phenotype Test This test evaluates the specific protein variants (Pi types) of Alpha-1-Antitrypsin in the blood.	Serum	2–3 weeks after sample receipt by the 7th of the month	2,500.00 AED	View
View test specifications and preparation Hide test specifications and preparation What it measures ["Alpha-1-Antitrypsin protein variants (Pi types)", "Quantitative and qualitative protein variants"] Parameters [{"name": "Alpha-1-Antitrypsin Phenotype", "reference_range": null}] Preparation ["No fasting required", "Complete Test Send Out Consent Form (Form 35)"] Indications ["Diagnosis of alpha-1 antitrypsin deficiency", "Assessment of risk for lung and liver disease", "Evaluation of unexplained respiratory or liver conditions"] Measurement technique Confirm with laboratory Codes LOINC: 55014-4 ICD-10: E88.01 Clinical summary This test evaluates the specific protein variants (Pi types) of Alpha-1-Antitrypsin in the blood.
TEST-6106 ALPL Gene Hypophosphatasia (Infantile) NGS Test This test identifies mutations in the ALPL gene associated with infantile hypophosphatasia.	Peripheral Whole Blood	3–4 Weeks	2,800.00 AED	View
View test specifications and preparation Hide test specifications and preparation What it measures ["ALPL gene mutations", "Single nucleotide variants", "Small insertions/deletions", "Copy number variations"] Parameters [] Preparation ["No special preparation such as fasting is required"] Indications ["Suspected infantile hypophosphatasia", "Low alkaline phosphatase levels", "Severe metabolic bone disorder"] Measurement technique Confirm with laboratory Codes LOINC: 82163-2 ICD-10: E83.30 Clinical summary This test identifies mutations in the ALPL gene associated with infantile hypophosphatasia.
TEST-3782 ALS2 Gene (Amyotrophic Lateral Sclerosis Type 2, Juvenile) Genetic Test This genetic test evaluates the ALS2 gene for pathogenic variants associated with juvenile-onset amyotrophic lateral sclerosis (JALS).	Peripheral Whole Blood (EDTA) or FTA Card	3–4 Weeks	2,800.00 AED	View
View test specifications and preparation Hide test specifications and preparation What it measures ["Pathogenic variants in the ALS2 gene", "Full coding region analysis"] Parameters [] Preparation ["No specific fasting required.", "Inform phlebotomist of any bleeding disorders or anticoagulant use."] Indications ["Suspicion of juvenile-onset amyotrophic lateral sclerosis (JALS)", "Family history of JALS", "Genetic risk assessment for motor neuron disease"] Measurement technique Confirm with laboratory Codes LOINC: 29527-8 ICD-10: G12.21 Clinical summary This genetic test evaluates the ALS2 gene for pathogenic variants associated with juvenile-onset amyotrophic lateral sclerosis (JALS).
TEST-5528 ALS2 Gene Primary Lateral Sclerosis, Juvenile Genetic Test This test identifies pathogenic variants in the ALS2 gene, which are the definitive cause of juvenile primary lateral sclerosis (JPLS) and infantile-onset ascending hereditary spas...	Whole Blood (EDTA), Extracted DNA, or FTA Card	21–28 Days (3–4 Weeks)	2,800.00 AED	View
View test specifications and preparation Hide test specifications and preparation What it measures ["Pathogenic variants in the ALS2 gene", "Copy number variations (CNV) in the ALS2 gene"] Parameters [{"name": "ALS2 Gene Sequencing", "reference_range": "No pathogenic variants detected"}, {"name": "Copy Number Variation (CNV) Analysis", "reference_range": "No pathogenic CNVs detected"}] Preparation ["No specific fasting required", "Inform lab of any medications"] Indications ["Suspected diagnosis of Juvenile Primary Lateral Sclerosis (JPLS)", "Suspected diagnosis of Infantile-Onset Ascending Hereditary Spastic Paralysis (IAHSP)", "Family history of JPLS or IAHSP", "Genetic counseling for families with affected individuals"] Measurement technique Confirm with laboratory Codes LOINC: 90202-2 ICD-10: G12.21 Clinical summary This test identifies pathogenic variants in the ALS2 gene, which are the definitive cause of juvenile primary lateral sclerosis (JPLS) and infantile-onset ascending hereditary spastic paralysis (IAHSP).
TEST-2829 ALX4 Gene (Frontonasal Dysplasia Type 2) Genetic Test This test identifies pathogenic variants in the ALX4 gene associated with Frontonasal Dysplasia Type 2 (FND2). It utilizes Next-Generation Sequencing (NGS) to provide comprehensive...	Whole Blood (Peripheral) or FTA Card Dried Blood Spot	3–4 Weeks	2,800.00 AED	View
View test specifications and preparation Hide test specifications and preparation What it measures ["Pathogenic variants in the ALX4 gene"] Parameters [] Preparation [] Indications ["Confirmation of clinical dysmorphology findings", "Guiding craniofacial surgical planning"] Measurement technique Confirm with laboratory Codes LOINC: 87611-7 ICD-10: Q75.8 Clinical summary This test identifies pathogenic variants in the ALX4 gene associated with Frontonasal Dysplasia Type 2 (FND2). It utilizes Next-Generation Sequencing (NGS) to provide comprehensive analysis.
TEST-5407 AMBN Gene Amelogenesis Imperfecta Type 1F Genetic Test This genetic test evaluates the AMBN gene for variants causing Amelogenesis Imperfecta Type 1F.	Peripheral whole blood (3–5 mL EDTA) or buccal swab	3–4 weeks from sample receipt	2,800.00 AED	View
View test specifications and preparation Hide test specifications and preparation What it measures ["AMBN gene variants", "Hypoplastic/hypomaturation type 1F amelogenesis imperfecta"] Parameters [] Preparation [] Indications ["Suspected diagnosis of Amelogenesis Imperfecta Type 1F", "Family history of Amelogenesis Imperfecta", "Genetic counselling for dental conditions"] Measurement technique Confirm with laboratory Codes LOINC: 94302-5 ICD-10: K00.5 Clinical summary This genetic test evaluates the AMBN gene for variants causing Amelogenesis Imperfecta Type 1F.
TEST-3384 AMHR2 Gene (Persistent Mullerian Duct Syndrome Type 2) Genetic Test This genetic test identifies pathogenic variants in the AMHR2 gene, confirming a diagnosis of Persistent Mullerian Duct Syndrome type 2 (PMDS) in individuals with a 46,XY karyotype...	Peripheral whole blood (EDTA tube)	3–4 weeks	2,800.00 AED	View
View test specifications and preparation Hide test specifications and preparation What it measures ["AMHR2 gene variants", "Single nucleotide variants (SNVs)", "Small insertions and deletions (indels)", "Copy number variations (CNVs)"] Parameters [] Preparation ["No fasting required", "Detailed family pedigree required prior to collection"] Indications ["Diagnosis of Persistent Mullerian Duct Syndrome type 2 (PMDS)", "Evaluation of 46,XY difference of sex development", "Infertility evaluation"] Measurement technique Confirm with laboratory Codes LOINC: 21659-2 ICD-10: Q55.8 Clinical summary This genetic test identifies pathogenic variants in the AMHR2 gene, confirming a diagnosis of Persistent Mullerian Duct Syndrome type 2 (PMDS) in individuals with a 46,XY karyotype.
TEST-5234 AMPD1 Gene Myopathy (Myoadenylate Deaminase Deficiency) Genetic Test This genetic test identifies pathogenic variants in the AMPD1 gene associated with myoadenylate deaminase deficiency.	Peripheral Whole Blood (EDTA) or Dried Blood Spot (DBS)	3 – 4 Weeks	2,800.00 AED	View
View test specifications and preparation Hide test specifications and preparation What it measures ["Pathogenic variants in the AMPD1 gene", "Genetic predisposition to myoadenylate deaminase deficiency"] Parameters [] Preparation ["No specific fasting required", "Avoid recent blood transfusions (within 2 weeks)"] Indications ["Diagnostic confirmation of suspected myoadenylate deaminase deficiency", "Family screening for individuals with a family history of the condition", "Evaluation of unexplained exercise intolerance or rhabdomyolysis"] Measurement technique Confirm with laboratory Codes LOINC: 51956-7 ICD-10: E79.2, Z15.89, Z13.79 Clinical summary This genetic test identifies pathogenic variants in the AMPD1 gene associated with myoadenylate deaminase deficiency.
TEST-5516 AMPD2 Gene Sequencing for Pontocerebellar Hypoplasia Type 9 Test This test identifies pathogenic variants in the AMPD2 gene associated with pontocerebellar hypoplasia type 9.	Peripheral whole blood	3–4 weeks	2,800.00 AED	View
View test specifications and preparation Hide test specifications and preparation What it measures ["Pathogenic variants in AMPD2 gene", "Single nucleotide variants", "Small insertions and deletions", "Copy number alterations"] Parameters [] Preparation [] Indications ["Diagnosis of pontocerebellar hypoplasia type 9", "Carrier testing in at-risk families"] Measurement technique Confirm with laboratory Codes LOINC: 55233-1 ICD-10: G31.89 Clinical summary This test identifies pathogenic variants in the AMPD2 gene associated with pontocerebellar hypoplasia type 9.
TEST-5801 AMPD2 Gene SPG63 Genetic Test This test detects pathogenic variants in the AMPD2 gene associated with Hereditary Spastic Paraplegia Type 63 (SPG63).	Peripheral whole blood (EDTA) or extracted genomic DNA	3-4 weeks from sample receipt	2,800.00 AED	View
View test specifications and preparation Hide test specifications and preparation What it measures ["Pathogenic variants in the AMPD2 gene", "Point mutations", "Small insertions/deletions", "Copy number variations"] Parameters [] Preparation [] Indications ["Clinical suspicion of Hereditary Spastic Paraplegia Type 63 (SPG63)", "Family history of SPG63", "Neurological examination findings consistent with SPG63"] Measurement technique Confirm with laboratory Codes LOINC: 95035-9 ICD-10: G11.4 Clinical summary This test detects pathogenic variants in the AMPD2 gene associated with Hereditary Spastic Paraplegia Type 63 (SPG63).

Category overview

Genetic: overview

Unlocking the blueprint of your DNA provides profound, proactive insights into your family’s future and personal health risks. Integrated within our advanced Biochemistry and molecular services, specialized Genetic testing evaluates inherited traits, metabolic predispositions, and carrier statuses. Utilizing cutting-edge diagnostic technology, comprehensive genetic screening offers the vital clarity needed to safely guide tailored medical strategies and family planning. As an undisputed leader in innovation among diagnostic labs in Dubai and the UAE, DNA Labs guarantees the highest standards of strict patient confidentiality, unparalleled diagnostic precision, and rapid reporting. Empower your health decisions with certainty—book your genetic testing in UAE, coordinate a secure sample collection, or connect with our specialized genetics team today.

Before booking

Use the test details as a conversation starter

The right diagnostic option depends on your reason for testing and individual circumstances. Check the listed specimen and timing, then confirm any preparation requirements with the ordering clinician or laboratory before collection.